Recursion Pharmaceuticals, Inc.
RXRX
$3.16
-$0.15-4.53%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.49% | -8.68% | 33.36% | 5.61% | 15.11% |
| Total Depreciation and Amortization | -7.66% | 1.00% | -7.44% | -11.77% | 23.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.73% | -23.06% | -36.41% | 37.47% | -36.06% |
| Change in Net Operating Assets | -137.80% | -173.06% | 140.63% | -174.80% | 700.70% |
| Cash from Operations | -30.64% | -76.03% | 60.74% | -53.58% | 42.09% |
| Capital Expenditure | 82.95% | 79.26% | -411.93% | 92.29% | -71.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 100.00% |
| Other Investing Activities | -2,293.75% | -- | 100.00% | 13.24% | -165.80% |
| Cash from Investing | -479.59% | 72.83% | 51.20% | 56.11% | 20.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.95% | -1.89% | -1.88% | -2.06% | -1.81% |
| Issuance of Common Stock | -- | -- | -47.06% | 153.47% | 143.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 177.97% | -- | -- | 100.00% | -116.58% |
| Cash from Financing | 63.49% | -102.63% | -47.48% | 157.36% | 140.97% |
| Foreign Exchange rate Adjustments | 121.22% | -283.61% | 11.66% | -79.81% | 91.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -22.11% | -202.26% | -34.90% | 439.94% | 126.30% |